Mar 05, 2012, 10.28 AM | Source: Reuters
Cipla said it had received government notices seeking Rs 425 crore due to over pricing of certain drugs.
The demands are contrary to the orders passed by the Supreme Court of India and are related to the same drugs under litigation, the drugmaker said in a statement.
The company has received a legal advice which says the entire amount demanded by the National Pharmaceutical Pricing Authority (NPPA) is not tenable and sustainable, Cipla said.
NPPA is a government body that fines drugmakers in India if they over price certain drugs that have been identified under the national list of essential medicines.
Ajcon Global is bullish on Cipla has recommended b
Vittal, a former partner with McKinsey & Company,
Ashwani Gujral of ashwanigujral.com advises buying
Cipla said its UK subsidiary has sold entire stake
Khambatta Securities is bullish on Cipla has recom